Conference - Boston, MA, United States
Recent changes in the healthcare system have put a greater focus on the development and availability of generic drugs. The pharmaceutical industry has responded by exploring alternative delivery methods, creating new test designs and, most notably, developing the first American biosimilar. These advances have been met with acclaim, but they do bring new challenges. Regulatory ambiguity in testing procedures delay generic developers, and legal action from originator drug companies restricts those focusing on biosimilars. This summit will further explore the scientific necessity of this subject, while guiding experts through their collective difficulties.
- Organization: ExL Pharma
Mon, Oct 05, 2015 - Tue, Oct 06, 2015
40 Dalton Street, 02115, Boston, MA, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
